Codis Significantly Invests in UK Spray-Drying Capacity for ASDs
With support from LSIMF, Codis is expanding its UK facility with the addition of a GEA PSD-4 commercial-scale spray dryer, making it the only CDMO in the UK to offer such capacity.
Global CDMO, Codis, has purchased a GEA Pharma-SD type PSD-4 solvent-capable spray dryer, significantly expanding its UK manufacturing capabilities. The company revealed, in a March 4, 2026 press release (1), that the newly purchased spray dryer will be added to its 400,000 square-foot facility in Haverhill, UK, and it expects the expanded facility will be operational in 2027.
The PSD4 is a large-scale, CGMP pharmaceutical spray dryer that has been designed for the production of batches up to 500 kg and a total capacity of 30,000 kg per year. This new spray dryer complements Codis’ existing platform — a PSD2 unit that supports pilot-scale and smaller commercial-scale production — and in combination will allow Codis to provide its clients with a seamless production pathway from development to large-scale commercial manufacturing (1).
This investment is being supported by the UK government’s Life Science and Innovative Manufacturing Fund (LSIMF), subject to the final agreement of terms and conditions (1). LSIMF is a capital grants fund, worth a total of GBP 520 million, that is aimed at supporting the economic growth of life science manufacturers and building future resilience against potential health emergencies (2).
“This milestone marks the next phase in Codis’ evolution as a global leader in spray drying and ASD,” said Nicolas Fortin, Chief Executive Officer of Codis, in a company press release (1). “The PSD4 significantly expands our ASD capacity and gives customers dedicated commercial‑scale throughput to bring more life‑changing medicines to market. We are grateful for the support of the UK government through the LSIMF, which enables us to accelerate this project and continue investing at our Haverhill site.”
Codis officially launched as a global CDMO specializing in commercial-scale spray drying, amorphous solid dispersions (ASD), and particle engineering technologies back in October 2025. The company was formed through the integration of Particle Dynamics based in the U.S. and the Haverhill, UK spray drying facility that had previously been operated by EUROAPI (3).
“Codis is built on a foundation of scale, quality, and global reach,” explained Fortin, in a company press release (3). “With a total of 40,000 m2 of manufacturing space, three GMP facilities and with 7 of regulatory approvals achieved, we are uniquely positioned to help pharmaceutical innovators accelerate therapies from development to market.”
References
Codis. Codis Unlocks Commercial-Scale Amorphous Solid Dispersions Manufacturing with GEA PSD4 Solvent Spray Dryer Investment. Press Release, March 4, 2026.
UK Gov. The Life Sciences Innovative Manufacturing Fund (LSIMF). Gov.uk (accessed March 9, 2025).
Codis. Codis Launches as Global CDMO for Commercial Spray Drying and Amorphous Solid Dispersions. Press Release, Oct. 14, 2025.